CC-chemokine ligand 2 facilitates conditioned place preference to methamphetamine through the activation of dopamine systems

Journal of Pharmacological Sciences

Volumn 125, Issue 1, 2014, Pages 68-73

  Wakida, Naoki ^a   Kiguchi, Norikazu ^a   Saika, Fumihiro ^a   Nishiue, Hideki ^a   Kobayashi, Yuka ^a   Kishioka, Shiroh ^a  

^a WAKAYAMA MEDICAL UNIVERSITY   (Japan)

Author keywords

Addiction; CC chemokine ligand 2 (CCL2); Chemokine; Inflammation; Monocyte chemoattractant protein 1 (MCP 1)

Indexed keywords

CHEMOKINE RECEPTOR CCR2; CHEMOKINE RECEPTOR CCR2 ANTAGONIST; METHAMPHETAMINE; MONOCYTE CHEMOTACTIC PROTEIN 1; RECOMBINANT CYTOKINE; RS 504393; TYROSINE 3 MONOOXYGENASE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONDITIONED PLACE PREFERENCE TEST; DOPAMINERGIC NERVE CELL; DOSE RESPONSE; DRUG DEPENDENCE; DRUG MECHANISM; ENZYME PHOSPHORYLATION; IMMUNOHISTOCHEMISTRY; MALE; METHAMPHETAMINE DEPENDENCE; MOUSE; NONHUMAN; NUCLEUS ACCUMBENS; PLACE PREFERENCE; PREFRONTAL CORTEX; REWARD; UPREGULATION; VENTRAL TEGMENTUM;

ANIMALS; BENZOXAZINES; CENTRAL NERVOUS SYSTEM STIMULANTS; CHEMOKINE CCL2; DISEASE MODELS, ANIMAL; DOPAMINERGIC NEURONS; DOSE-RESPONSE RELATIONSHIP, DRUG; MALE; METHAMPHETAMINE; MICE; MICE, INBRED C57BL; NUCLEUS ACCUMBENS; PREFRONTAL CORTEX; RECEPTORS, CCR2; SPIRO COMPOUNDS; SUBSTANCE ABUSE DETECTION; SUBSTANCE-RELATED DISORDERS; TYROSINE 3-MONOOXYGENASE; VENTRAL TEGMENTAL AREA;

EID: 84902165239     PISSN: 13478613     EISSN: 13478648     Source Type: Journal    
DOI: 10.1254/jphs.14032FP     Document Type: Article

References (32)

1. Degenhardt L, Hall W. Extent of illicit drug use and dependence, and their contribution to the global burden of disease. Lancet. 2012;379:55-70.
2. Pickens CL, Airavaara M, Theberge F, Fanous S, Hope BT, Shaham Y. Neurobiology of the incubation of drug craving. Trends Neurosci. 2011;34:411-420.
3. Luscher C, Malenka RC. Drug-evoked synaptic plasticity in addiction: from molecular changes to circuit remodeling. Neuron. 2011;69:650-663.
4. Sulzer D. How addictive drugs disrupt presynaptic dopamine neurotransmission. Neuron. 2011;69:628-649.
5. Russo SJ, Nestler EJ. The brain reward circuitry in mood disorders. Nat Rev Neurosci. 2013;14:609-625.
6. Yao L, Fan P, Arolfo M, Jiang Z, Olive MF, Zablocki J, et al. Inhibition of aldehyde dehydrogenase-2 suppresses cocaine seeking by generating THP, a cocaine use-dependent inhibitor of dopamine synthesis. Nat Med. 2010;16:1024-1028.
7. Fineberg AM, Ellman LM. Inflammatory cytokines and neurological and neurocognitive alterations in the course of schizophrenia. Biol Psychiatry. 2013;73:951-966.
8. Drouin-Ouellet J, Cicchetti F. Inflammation and neurodegeneration: the story 'retolled'. Trends Pharmacol Sci. 2012;33:542-551.
9. Ubogu EE, Cossoy MB, Ransohoff RM. The expression and function of chemokines involved in CNS inflammation. Trends Pharmacol Sci. 2006;27:48-55. (Pubitemid 43063124)
10. McCusker RH, Kelley KW. Immune-neural connections: how the immune system's response to infectious agents influences behavior. J Exp Biol. 2013;216:84-98.
11. Gouwy M, Struyf S, Proost P, Van Damme J. Synergy in cytokine and chemokine networks amplifies the inflammatory response. Cytokine Growth Factor Rev. 2005;16:561-580. (Pubitemid 41505517)
12. Guyon A, Skrzydelski D, De Giry I, Rovere C, Conductier G, Trocello JM, et al. Long term exposure to the chemokine CCL2 activates the nigrostriatal dopamine system: a novel mechanism for the control of dopamine release. Neuroscience. 2009;162: 1072-1080.
13. Rostene W, Kitabgi P, Parsadaniantz SM. Chemokines: a new class of neuromodulator? Nat Rev Neurosci. 2007;8:895-903.
14. Crews FT, Zou J, Qin L. Induction of innate immune genes in brain create the neurobiology of addiction. Brain Behav Immun. 2011;25 Suppl 1:S4-S12.
15. Ikegami D, Narita M, Imai S, Miyashita K, Tamura R, Narita M, et al. Epigenetic modulation at the CCR2 gene correlates with the maintenance of behavioral sensitization to methamphetamine. Addict Biol. 2010;15:358-361.
16. Dietz DM, Sun H, Lobo MK, Cahill ME, Chadwick B, Gao V, et al. Rac1 is essential in cocaine-induced structural plasticity of nucleus accumbens neurons. Nat Neurosci. 2012;15:891-896.
17. Mandyam CD, Wee S, Eisch AJ, Richardson HN, Koob GF. Methamphetamine self-administration and voluntary exercise have opposing effects on medial prefrontal cortex gliogenesis. J Neurosci. 2007;27:11442-11450. (Pubitemid 47621323)
18. Glass CK, Saijo K, Winner B, Marchetto MC, Gage FH. Mechanisms underlying inflammation in neurodegeneration. Cell. 2010;140:918-934.
19. Lazennec G, Richmond A. Chemokines and chemokine receptors: new insights into cancer-related inflammation. Trends Mol Med. 2010;16:133-144.
20. Gao YJ, Ji RR. Chemokines, neuronal-glial interactions, and entral processing of neuropathic pain. Pharmacol Ther. 2010; 126:56-68.
21. Madrigal JL, Leza JC, Polak P, Kalinin S, Feinstein DL. Astrocyte-derived MCP-1 mediates neuroprotective effects of noradrenaline. J Neurosci. 2009;29:263-267.
22. Zhang J, Shi XQ, Echeverry S, Mogil JS, De Koninck Y, Rivest S. Expression of CCR2 in both resident and bone marrow-derived microglia plays a critical role in neuropathic pain. J Neurosci. 2007;27:12396-12406. (Pubitemid 350085465)
23. Nestler EJ. Is there a common molecular pathway for addiction? Nat Neurosci. 2005;8:1445-1449. (Pubitemid 41573654)
24. Schwarz JM, Hutchinson MR, Bilbo SD. Early-life experience decreases drug-induced reinstatement of morphine CPP in adulthood via microglial-specific epigenetic programming of anti-inflammatory IL-10 expression. J Neurosci. 2011;31:17835-17847.
25. Nakajima A, Yamada K, Nagai T, Uchiyama T, Miyamoto Y, Mamiya T, et al. Role of tumor necrosis factor-alpha in methamphetamine-induced drug dependence and neurotoxicity. J Neurosci. 2004;24:2212-2225. (Pubitemid 38314553)
26. He J, Crews FT. Increased MCP-1 and microglia in various regions of the human alcoholic brain. Exp Neurol. 2008;210:349-358.
27. Kitamura O, Takeichi T, Wang EL, Tokunaga I, Ishigami A, Kubo S. Microglial and astrocytic changes in the striatum of methamphetamine abusers. Leg Med (Tokyo). 2010;12:57-62.
28. Sekine Y, Ouchi Y, Sugihara G, Takei N, Yoshikawa E, Nakamura K, et al. Methamphetamine causes microglial activation in the brains of human abusers. J Neurosci. 2008;28:5756-5761.
29. Narita M, Miyatake M, Narita M, Shibasaki M, Shindo K, Nakamura A, et al. Direct evidence of astrocytic modulation in the development of rewarding effects induced by drugs of abuse. Neuropsychopharmacology. 2006;31:2476-2488. (Pubitemid 44607065)
30. Schwarz JM, Bilbo SD. Adolescent morphine exposure affects long-term microglial function and later-life relapse liability in a model of addiction. J Neurosci. 2013;33:961-971.
31. Fujita Y, Kunitachi S, Iyo M, Hashimoto K. The antibiotic minocycline prevents methamphetamine-induced rewarding effects in mice. Pharmacol Biochem Behav. 2012;101:303-306.
32. Maeda T, Kiguchi N, Fukazawa Y, Yamamoto A, Ozaki M, Kishioka S. Peroxisome proliferator-activated receptor gamma activation relieves expression of behavioral sensitization to methamphetamine in mice. Neuropsychopharmacology. 2007;32:1133-1140. (Pubitemid 46631976)